AKEBIA THERAPEUTICS INC (AKBA) competitors & alternatives
Health Care · NASDAQ
AKEBIA THERAPEUTICS INC (AKBA)'s top competitors and alternatives — its most similar public companies — include Amgen (AMGN), MINERALYS THERAPEUTICS INC (MLYS), TRAVERE THERAPEUTICS INC (TVTX), LEXICON PHARMACEUTICALS INC (LXRX), DaVita (DVA), ARDELYX INC (ARDX), UNICYCIVE THERAPEUTICS INC (UNCY), PROKIDNEY CORP CLASS A (PROK), VERA THERAPEUTICS INC CLASS A (VERA), MANNKIND CORP (MNKD), Baxter International (BAX) and AURINIA PHARMACEUTICALS INC (AUPH). These are AKEBIA THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AKBA competitors & alternatives
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.05 (as of 2026-07-22) · market cap $197.7B
-
MINERALYS THERAPEUTICS INCMLYSHealth Care
Mineralys is a clinical-stage biopharmaceutical company pursuing FDA approval of lorundrostat, a selective aldosterone synthase inhibitor targeting resistant…
$27.01 (as of 2026-07-22) · market cap $2.4B
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
LEXICON PHARMACEUTICALS INCLXRXHealth Care
An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by…
$2.25 (as of 2026-07-22) · market cap $1.0B
-
DaVitaDVAHealth Care
Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant…
$232.08 (as of 2026-07-22) · market cap $15.0B
-
ARDELYX INCARDXHealth Care
Ardelyx commercializes tenapanor-based therapies (IBSRELA for IBS-C, XPHOZAH for kidney disease hyperphosphatemia) with a pipeline of next-generation NHE3…
$5.08 (as of 2026-07-22) · market cap $1.3B
-
UNICYCIVE THERAPEUTICS INCUNCYHealth Care
A clinical-stage biotechnology firm developing nanoparticle-based and novel therapies to address significant unmet medical needs in kidney disease.
$5.57 (as of 2026-07-22) · market cap $149M
-
PROKIDNEY CORP CLASS APROKHealth Care
ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in…
$1.53 (as of 2026-07-22) · market cap $462M
-
VERA THERAPEUTICS INC CLASS AVERAHealth Care
Vera Therapeutics is developing atacicept, a first-in-class B-cell modulator targeting both BAFF and APRIL for autoimmune kidney diseases including IgAN,…
$36.06 (as of 2026-07-22) · market cap $2.6B
-
MANNKIND CORPMNKDHealth Care
MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic…
$3.84 (as of 2026-07-22) · market cap $1.2B
-
Baxter InternationalBAXHealth Care
A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds,…
$21.74 (as of 2026-07-22) · market cap $11.5B
-
AURINIA PHARMACEUTICALS INCAUPHHealth Care
Aurinia is a specialty pharma company commercializing LUPKYNIS, the first oral calcineurin inhibitor approved for lupus nephritis, with strong profitability…
$15.33 (as of 2026-07-22) · market cap $2.0B
Not quite? Describe exactly what you want →
Peers are AKEBIA THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AKEBIA THERAPEUTICS INC (AKBA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.